PD-L1 Agonist Treatment for Cerebral Vasospasm

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for cerebral vasospasm following aneurysmal subarachnoid hemorrhage are inadequate, as they lack effective immunomodulatory agents to prevent or treat the condition, and the mechanisms of aberrant inflammation are poorly understood.

Innovation Solution

The use of PD-1 agonists, specifically soluble Programmed Death Ligand 1 (PD-L1) or its analogues, to inhibit PD-1 expressing myeloid cells, which are identified as mediators of cerebral vasospasm, by preventing their migration into the brain, thereby addressing the inflammatory response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current standard treatments (nimodipine and supportive care) are used for cerebral vasospasm, then the treatment approach is simple and well-established, but the effectiveness is insufficient for preventing or treating the condition

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidcomplexity of treatment approach

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent introduces PD-L1 as an intermediary agent that binds to PD-1 receptors on myeloid cells, blocking their pro-inflammatory activity. This mediator approach allows for targeted immunomodulation without requiring complex surgical or mechanical interventions, thereby improving effectiveness while maintaining treatment simplicity

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the immunological parameter profile by administering PD-L1 to shift the balance from pro-inflammatory to anti-inflammatory states. This parameter change approach addresses the inadequacy of current treatments by modifying the underlying inflammatory response without adding procedural complexity

Inventive Principle:

Principle #35Parameter changes

2Reliability

If immunomodulatory agents are developed to target aberrant inflammation, then the effectiveness against cerebral vasospasm would be improved, but the mechanisms are currently poorly understood making development difficult

Engineering Contradiction:

Improveeffectiveness of immunomodulatory treatmentVSAvoidease of drug development

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent extracts and isolates the specific PD-1/PD-L1 interaction mechanism from the complex inflammatory response. By focusing on this specific pathway rather than attempting to modulate the entire inflammatory cascade, the patent simplifies drug development while targeting the root cause of cerebral vasospasm

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

Instead of trying to suppress inflammation through traditional anti-inflammatory agents, the patent uses PD-L1 to actively engage and regulate the PD-1 pathway, inverting the approach from suppression to regulated engagement. This provides a more precise mechanism for treating vasospasm while simplifying the development process

Inventive Principle:

Principle #13The other way round (Inversion)

Data Source

PatentUS20220252599A1Compositions and methods for treating cerebral vasospasm

Publication Date: 2022.08.11 JOHNS HOPKINS UNIVERSITY

AI summary

The present invention relates to the field of inflammation. More specifically, the present invention provides compositions and methods for treating cerebral inflammation and associated sequelae thereof including cerebral vasospasm. In one embodiment, a method for treating cerebral vasospasm in a patient comprises the step of administering to the patient a PD-1 agonist, wherein a blood sample obtained from the patient comprises elevated PD-1 expression on monocytes relative to a control.